Durasphere Post-Approval Studies Should Focus On Subgroups - FDA Panel
This article was originally published in The Gray Sheet
Advanced UroScience is anticipating a worldwide launch of the injectable bulking agent Durasphere sometime in the fourth quarter, following an approvable recommendation from FDA's Gastroenterology and Urology Devices Panel at its July 29 meeting in Rockville, Maryland.
You may also be interested in...
Advanced UroScience's post-approval study of its Durasphere bulking agent for treatment of female stress urinary incontinence due to intrinsic sphincter deficiency will focus on evaluating the durability of the product, the company reports.
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.